JANX
What one share of Janux Therapeutics holds
Pharmaceutical Preparations
We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Janux Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.38 |
|---|---|
| Profit | −$1.64 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.67 |
| Cash and investments | $0.45 |
| Book value | $15.19 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$7.41 | $0.00 | −$4.77 | — | −$13.99 |
| 2021 | $0.15 | −$1.39 | $0.06 | −$0.78 | — | $8.88 |
| 2022 | $0.21 | −$1.52 | $0.16 | −$1.19 | — | $7.71 |
| 2023 | $0.18 | −$1.32 | $0.04 | −$1.19 | — | $7.45 |
| 2024 | $0.20 | −$1.28 | $0.01 | −$0.82 | — | $17.32 |
| 2025 | $0.16 | −$1.83 | $0.02 | −$1.34 | — | $15.85 |